Clover Biopharmaceuticals (HKSE:02197) Cash-to-Debt : 2.29 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Clover Biopharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.29.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Clover Biopharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Clover Biopharmaceuticals's Cash-to-Debt or its related term are showing as below:

HKSE:02197' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.29 Med: 12.74 Max: 42.2
Current: 2.29

During the past 5 years, Clover Biopharmaceuticals's highest Cash to Debt Ratio was 42.20. The lowest was 2.29. And the median was 12.74.

HKSE:02197's Cash-to-Debt is ranked worse than
64.86% of 1528 companies
in the Biotechnology industry
Industry Median: 6.315 vs HKSE:02197: 2.29

Clover Biopharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Clover Biopharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Clover Biopharmaceuticals Cash-to-Debt Chart

Clover Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

12.74

36.14

42.20

4.63

2.29

Clover Biopharmaceuticals Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			42.20	28.46	4.63	2.85	2.29

Competitive Comparison of Clover Biopharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Clover Biopharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clover Biopharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Cash-to-Debt falls into.

Clover Biopharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Clover Biopharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	838.116	/	(357.226	+	8.589)
	=	2.29

Clover Biopharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	838.116	/	(357.226	+	8.589)
	=	2.29

Clover Biopharmaceuticals (HKSE:02197) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Clover Biopharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Clover Biopharmaceuticals (HKSE:02197) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN

Website

https://www.cloverbiopharma.com

Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.

Executives

Liang Peng	2101 Beneficial owner
Liang Joshua G	2501 Other
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Aut-xxi Investment Holdings Limited	2201 Interest of corporation controlled by you
Jnry V Holdings Limited	2101 Beneficial owner
Aut-xxi Hk Holdings Limited	2101 Beneficial owner
Aut-xxi Holdings Limited	2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Super Novel International Limited	2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines